SIGA Technologies (SIGA) AI Stock Analysis

• Market Cap: $471.51M
• Dividend Yield: 10.13%
• Average Volume (3M): 350.48K
• Price to Earnings (P/E): 6.3
• Beta (1Y): 0.96
• Revenue Growth: 3.86%
• EPS Growth: -2.60%
• Country: US
• Employees: 46
• Sector: Healthcare
• Sector Strength: 38
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.49
• Shares Outstanding: 71,441,086
• 10 Day Avg. Volume: 371,752
• 30 Day Avg. Volume: 350,479
• PEG Ratio: -0.57
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 3.09
• P/FCF Ratio: 8.79
• Enterprise Value/Market Cap: 0.61
• Enterprise Value/Revenue: 1.59
• Enterprise Value/Gross Profit: 3.78
• Enterprise Value/Ebitda: 2.83
• 1Y Price Target: $8.50
• Price Target Upside: 28.79% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 82 Outperform
• Price Target: $8.50 ▲(28.79% Upside)

SIGA Technologies demonstrates strong financial performance with high profitability and a robust balance sheet. The positive earnings call, highlighting revenue growth and strategic progress, further boosts confidence. Technical indicators support a bullish outlook, and the stock's valuation suggests it is undervalued. However, stagnant revenue growth and regulatory challenges are areas to watch.

SIGA Technologies Business Overview & Revenue Model

Company Description

SIGA Technologies, Inc. is a pharmaceutical company that specializes in the development and commercialization of solutions for unmet needs in health security. Primarily focusing on the sectors of infectious disease, biodefense, and antiviral research, SIGA's core product is TPOXX (tecovirimat), an antiviral medication approved for the treatment of smallpox and other orthopoxvirus infections. The company aims to address gaps in public health preparedness by providing effective countermeasures against potential biological threats.

How the Company Makes Money

SIGA Technologies generates revenue primarily through government contracts and grants related to health security, particularly in biodefense. The company's revenue streams are significantly bolstered by sales of its flagship product, TPOXX, to the U.S. government for the Strategic National Stockpile. Additionally, SIGA seeks to expand its market internationally by entering into partnerships and agreements with other governments and organizations interested in stockpiling antiviral treatments for orthopoxvirus infections. Licensing agreements and collaborations with other pharmaceutical entities also contribute to SIGA's earnings.

SIGA Technologies Financial Statement Overview

Summary

SIGA Technologies exhibits strong financial health with high profitability, a robust balance sheet with no debt, and sufficient cash flow generation. The company demonstrates excellent cost control and capital management. However, stagnant revenue growth and a decline in operating cash flow are areas to monitor closely for future financial performance.

Income Statement

SIGA Technologies has shown strong profitability with consistent gross and net profit margins over the years. The gross profit margin remains high at 100% in the latest year, indicating effective cost management. The net profit margin, although slightly reduced from the previous year, is still robust at 42.7%. However, the revenue growth has been stagnant, with a slight decrease of 0.9% from the prior year, which could suggest a plateau in sales expansion.

Balance Sheet

The company maintains a solid financial position with no debt, reflected in a debt-to-equity ratio of 0. The equity ratio is strong at 88.3%, indicating financial stability and a low-risk profile. Return on equity (ROE) is healthy at 27.4%, showcasing effective use of equity financing to generate profits. The absence of debt reduces financial risk significantly.

Cash Flow

Operating cash flow has decreased by 48.6% compared to the previous year, which could be a concern if the trend continues. However, free cash flow remains positive, indicating the company can cover its capital expenditures. The free cash flow to net income ratio is satisfactory, showing that profits are backed by cash generation. The decline in cash flow growth rate is a potential risk area.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	179.64M	138.72M	139.92M	110.78M	133.67M	124.96M
Gross Profit	75.80M	95.12M	122.09M	77.82M	107.13M	99.22M
EBITDA	101.32M	70.52M	84.16M	43.22M	89.62M	85.03M
Net Income	82.18M	59.21M	68.07M	33.90M	69.45M	56.34M
Balance Sheet
Total Assets	235.33M	244.34M	254.35M	195.04M	214.73M	149.83M
Cash, Cash Equivalents and Short-Term Investments	182.46M	155.40M	150.15M	98.79M	103.14M	117.89M
Total Debt	0.00	546.82K	564.01K	528.17K	466.83K	449.94K
Total Liabilities	26.02M	28.53M	57.49M	24.88M	40.41M	20.04M
Stockholders Equity	209.31M	215.80M	196.86M	170.16M	174.31M	129.79M
Cash Flow
Free Cash Flow	119.01M	48.72M	94.78M	41.61M	11.44M	71.50M
Operating Cash Flow	119.07M	48.76M	94.80M	41.61M	11.49M	71.52M
Investing Cash Flow	-65.16K	-42.45K	-21.69K	0.00	-50.62K	-15.50K
Financing Cash Flow	-43.49M	-43.46M	-43.42M	-45.96M	-26.20M	-114.60M

SIGA Technologies Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGA, the sentiment is Neutral. The current price of 6.6 is below the 20-day moving average (MA) of 6.82, above the 50-day MA of 6.51, and above the 200-day MA of 5.86, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 46.94 is Neutral, neither overbought nor oversold. The STOCH value of 20.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SIGA.

SIGA Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	82 Outperform	$471.51M	6.32	43.61%	10.13%	3.86%	-2.60%
ORGO	58 Neutral	$574.65M	928.57	-4.92%	―	5.35%	-432.51%
Sector *	51 Neutral	$7.39B	0.42	-62.86%	2.37%	15.61%	-1.95%
EBS	51 Neutral	$331.09M	―	-21.63%	―	-18.56%	76.88%
AQST	48 Neutral	$391.35M	―	77.48%	―	5.29%	-37.31%
EVO	47 Neutral	$1.39B	―	-20.41%	―	0.45%	-125.61%
RGC	―	$6.66B	―	-48.45%	―	―	―

SIGA Technologies Corporate Events

SIGA Technologies Holds Annual Stockholders Meeting

On June 10, 2025, SIGA Technologies held its Annual Meeting of Stockholders, where key decisions were made, including the election of eight directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and the approval of an amendment to limit officer liability. The Board also amended the company’s By-laws to designate exclusive legal forums for certain claims, reflecting a strategic move to streamline legal processes and potentially reduce litigation costs.